Millennium Management LLC Sells 343,224 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Millennium Management LLC lessened its position in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 9.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 3,413,448 shares of the company's stock after selling 343,224 shares during the period. Millennium Management LLC owned approximately 4.99% of COMPASS Pathways worth $12,903,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new stake in COMPASS Pathways in the fourth quarter valued at approximately $41,000. Flagship Harbor Advisors LLC acquired a new stake in COMPASS Pathways in the fourth quarter valued at approximately $43,000. Wealthfront Advisers LLC acquired a new stake in COMPASS Pathways in the fourth quarter valued at approximately $43,000. Conservest Capital Advisors Inc. grew its stake in COMPASS Pathways by 28.9% in the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock valued at $51,000 after acquiring an additional 3,000 shares during the period. Finally, Simplify Asset Management Inc. acquired a new stake in COMPASS Pathways in the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 46.19% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $45.00 target price on shares of COMPASS Pathways in a report on Monday, May 12th. Cantor Fitzgerald restated an "overweight" rating and issued a $12.00 target price on shares of COMPASS Pathways in a report on Tuesday. Stifel Nicolaus assumed coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a "buy" rating and a $11.00 target price on the stock. Finally, Canaccord Genuity Group dropped their target price on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $18.83.

COMPASS Pathways Stock Up 0.3%

Shares of CMPS stock traded up $0.01 during trading hours on Thursday, reaching $4.23. The company had a trading volume of 323,003 shares, compared to its average volume of 1,130,330. The business has a fifty day simple moving average of $3.52 and a 200-day simple moving average of $3.91. The company has a market cap of $393.12 million, a price-to-earnings ratio of -1.93 and a beta of 2.27. COMPASS Pathways plc has a 12 month low of $2.49 and a 12 month high of $8.54. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.03. On average, research analysts expect that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.